Going forward, CRC models will be used to explore drug–nutraceutical synergies: for example, combining an anti-EGFR antibody with a polyphenol to achieve additive anti-proliferative effects, or using omega-3 fatty acids alongside immunotherapy to mitigate treatment-related inflammation. Here, EGFR is linked to colorectal carcinoma.